After a decade of the capital gains-led investment focus, investors are now exploring income funds to weather the storm in global financial markets. Invesco says that cash flows today are preferable to uncertain capital gains tomorrow.
The investment management firm compares the Sharpe Ratios (a measure of returns relative to risk) since the 1950s and says that during periods of macro uncertainty and high inflation, high-yield stocks gave better risk-adjusted returns.
Over the past 10 years, bond yields have largely stayed in the negative, while equities have paid a higher yield than bonds. However, the situation is a bit different now as the dividend yield has dropped below 2% for the first time since the late 1990s. Invesco gives a chart comparing the rising numbers of non-dividend paying companies in the past couple of years.
“Investors will need to become more accepting of greater macro instability and central banks that are less willing to backstop financial markets. In the past, income has played a much greater role in returns under these conditions,” says writes Benjamin Jones, Director of Macro Research at Invesco.
The investment management firm warns that finding income funds is difficult, and screening assets on yield alone may not be the best approach as future yields may be influenced by several other factors than just macro.
Read more

Global Trade
Trump ignites global trade war / Reactions
The USA itself will be the victim of Trump’s trade policy.

Private Debt
The case for private debt in real asset financing
What makes the combination of private debt and real assets particularly compelling in today’s market?

Schroders
Looking ahead: 30-year return forecasts
Higher returns are expected across asset classes, driven by stronger productivity growth for equities and elevated long-term central bank rate projections for bonds.

Quant Investing
AI and quantitative investing
Artificial intelligence applications go way beyond stock selection.

Bellevue Asset Management
Demographics and AI drive MedTech stocks
MedTech investment case: What makes it attractive, which trends stand out?